First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
1/2상
조기 종료
NCT05086315
| 대상 질환 | Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia Refractory, Myelodysplastic Syndromes, Blastic Plasmacytoid Dendritic Cell Neoplasia |
|---|
| 임상 단계 | 1/2상 |
|---|
| 스폰서 | Sanofi |
|---|
| 상태 | 조기 종료 |
|---|
| 참여자 수 | 101 명 |
|---|
| 중재(약물) | SAR443579 |
|---|
| 시작일 | 2021년 12월 8일 |
|---|
| 완료일 | 2025년 6월 13일 |
|---|
| 결과 공개일 | 2026년 7월 6일 |
|---|
요약
This is an open-label, multicenter, Phase 1/Phase 2, dose escalation and dose expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics and anti-leukemic activity of SAR443579 in various hematological malignancies.
Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLTs)
Cycle 1 Day 1 up to Cycle 1 Day 28. Each cycle duration in induction period was 28 days. · Participants
| Dose Escalation - Adult Arm: SAR443579 10-100 mcg/kg | 0 Participants |
|---|
| Dose Escalation - Adult Arm: SAR443579 30-300 mcg/kg | 0 Participants |
|---|
| Dose Escalation - Adult Arm: SAR443579 750 mcg/kg | 1 Participants |
|---|
| Dose Escalation - Adult Arm: SAR443579 800 mcg/kg | 0 Participants |
|---|
| Dose Escalation - Adult Arm: SAR443579 100-1000 mcg/kg | 0 Participants |
|---|
| Dose Escalation - Adult Arm: SAR443579 300-1000 mcg/kg | 0 Participants |
|---|
Dose Escalation (Cohort C): Number of Participants With Dose Limiting Toxicities
Cycle 1 Day 1 to Cycle 1 Day 28. Each cycle duration in induction period was 28 days.
Dose Expansion (Cohorts A1, A2 and D): Composite Complete Remission (CRc) Rate
Tumors were assessed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until disease relapse, unacceptable AE, discontinuation, or death, whichever occurred first. Maximum treatment duration was 20.9 weeks. · percentage of participants
| Dose Expansion - Adult Arm (Cohort A1): SAR443579 1000 mcg/kg | 5.0 percentage of participants |
|---|
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.